newsfilter
← Latest News
Andreessen Horowitz·

Investing in Boltz

Summary

  • Boltz is revolutionizing drug discovery by providing widely adopted AI molecular models that enable scientists to predict interactions & design molecules computationally before synthesis.
  • The company's founders, Gabriele Corso, Jeremy Wohlwend, & Saro Passaro, leveraged their AI research & molecular science expertise to scale open-source models to every top 20 pharmaceutical company.
  • Boltz measures AI activity in "molecular tokens," creating a usage-based business model where customers pay for computational intelligence consumption similar to lab reagents.
  • This approach allows scientists to retain ownership of created molecules while accessing frontier biomolecular intelligence for routine discovery campaigns.
  • Boltz Lab offers user-friendly interfaces for biologists & chemists, while the Boltz API integrates capabilities into existing workflows & agentic harnesses like Claude Code & Codex.
  • Weekly molecular token consumption has risen approximately 50-fold in the last 4 months following the launch of BoltzMol-1 & BoltzProt-1.
  • Commercial models are currently deployed at major pharmaceutical companies including Pfizer, GSK, Takeda, & BMS, with options for training exclusive versions on proprietary data.
  • The company recently secured an $110M Series A funding round to invest further in research, compute, & data to build more capable models.

a16z invests in Boltz’s Series A

Keywords
Bio + Healthcare, Investment News